You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for MS 21570
MS 21570 is a GPR171 antagonist (IC50 = 220 nM). Inhibits BigLEN (Cat.No. 6304) mediated increases in [35S]GTPγS binding in hypothalamic membranes and hyperpolarization of basolateral amygdala pyramidal neurons. Reduces anxiety-like behavior and fear conditioning in mice.
Compound Libraries for MS 21570
Technical Data for MS 21570
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for MS 21570
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for MS 21570
The following data is based on the product molecular weight 237.34. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.21 mL||21.07 mL||42.13 mL|
|5 mM||0.84 mL||4.21 mL||8.43 mL|
|10 mM||0.42 mL||2.11 mL||4.21 mL|
|50 mM||0.08 mL||0.42 mL||0.84 mL|
References for MS 21570
References are publications that support the biological activity of the product.
Bobeck et al (2017) The BigLEN-GPR171 peptide receptor system within the basolateral amygdala regulates anxiety-like behavior and contextual fear conditioning. Neuropsychopharmacology 42 2527 PMID: 28425495
If you know of a relevant reference for MS 21570, please let us know.
View Related Products by Product Action
Keywords: MS 21570, MS 21570 supplier, MS21570, GPR171, antagonists, antagonism, bigLEN, anxiety, 6298, Tocris Bioscience
1 Citation for MS 21570
Citations are publications that use Tocris products. Selected citations for MS 21570 include:
Richard D et al (2021) The GPR171 pathway suppresses T cell activation and limits antitumor immunity. Nat Commun 12 5857 PMID: 34615877
Do you know of a great paper that uses MS 21570 from Tocris? Please let us know.
Reviews for MS 21570
There are currently no reviews for this product. Be the first to review MS 21570 and earn rewards!
Have you used MS 21570?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Peptides Involved in Appetite Modulation Scientific Review
Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.
Stem Cells Scientific Review
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.